Christopher Porter is the Sir John Monash Distinguished Professor and Director of the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University. He holds fellowships with the American Association of Pharmaceutical Scientists and the Royal Australian Chemical Institute. His research focuses on drug delivery systems, lymphatic transport, and nanomedicines, with significant contributions to lipid-based formulations and dendrimer technologies. Key achievements include the Glyph® lymphatic targeting platform (Phase 2 clinical trial) and the DEP® dendrimer system (Phase 2 clinical trial). Education: Undergraduate and graduate studies at the University of Nottingham. Key Awards: Clarivate Highly Cited Researcher (2015–2024), APSA Medal (2017), Honorary Doctorate (Uppsala University, 2018). Research interests span oral bioavailability enhancement, lipid-modified drug systems, and translational drug delivery. His work has generated over $30M in funding and 15+ patent families. Notable collaborations include PureTech Health/Seaport Therapeutics and Starpharma.
Dr. Sebastian Köhler is a postdoctoral Researcher at the Department of Physical Chemistry within Lund University's Faculty of Engineering . He is actively affiliated with both NanoLund: Centre for Nanoscience and the LTH Profile Area: Nanoscience and Semiconductor Technology , contributing to interdisciplinary research at the intersection of nanomaterials and biological systems. Physical Chemistry Researcher Postdoctoral Fellow NanoLund Centre Member LTH Profile Area Participant His research focuses on nanoparticle-biomolecule interactions , particularly peptide-coated TiO2 nanoparticles for antimicrobial applications. Current work explores structural control of bio-based polymers and surfactants, with emphasis on interfacial properties and membrane interactions. Collaborations span microbiology, pharmacology, and advanced materials characterization. Key research trends include photocatalytic degradation of bacterial components , conformational regulation of antimicrobial peptides , and bio-inspired nanoparticle design . Methodologies employ small-angle X-ray scattering , quartz crystal microbalance , and colloidal stability analysis to understand nanoscale biological interfaces.
Alf Garcia-Bennett is an Associate Professor in the School of Natural Sciences at Macquarie University. His research focuses on the development of nanomedicine technologies, including mesoporous silica-based drug delivery systems, plasmonic nanoparticles for biosensing, and advanced biomaterials for cancer therapy and tissue engineering. He leads projects such as the ARC Training Centre for Facilitated Advancement of Australia's Bioactives (FAAB) and investigations into next-generation immunotherapies through novel adjuvant designs. Projects: FAAB (2022-2027), Next Generation Adjuvants (2020-2025), Multi-functional SEM for High-throughput Analysis (2017-ongoing) Key Research Areas: Nanoparticle drug delivery, protein corona dynamics, transdermal drug penetration, 3D cancer metastasis models, and plasmonic biosensors. His work integrates materials science with biomedical applications, with notable contributions to the design of porous silica platforms for controlled drug release, plasmonic nanostar technologies, and experimental models for cancer micrometastasis. Collaborations span institutions globally, emphasizing translational research in bioactives and nanomedicine.
Professor Lisa Methven is a faculty member at the University of Reading, specializing in sensory and consumer science, flavor chemistry, and food product development. She leads the Sensory Science Centre and serves as Programme Director for the BSc Food Science with Business. Her research focuses on improving food palatability for older adults, investigating causes of individual sensory differences, and enhancing vegetable consumer acceptability. She holds a BSc (Hons) and PhD in relevant fields. Key grants include a 2008-2012 Research into Ageing grant and a multisite New Dynamics of Ageing project. She is a Fellow of the Institute of Food Science and Technology and actively involved in the SCI Food Group. Her work spans food fortification strategies, aging nutrition, and sensory perception studies. Notable contributions include developing protein-fortified recipes for older adults and studying the impacts of physical activity on appetite. External Activities: Committee member of SCI Food Group, Professional Food Sensory Group (PFSG) member Labs/Teams: Sensory Science Centre, Food4Years Network (improving foods for aging populations) Grants: Over £1M in grants focused on aging nutrition and sensory science
Kuldeep Bansal is a Lecturer and Project Researcher at the Faculty of Science and Engineering, Department of Pharmacy at Åbo Akademi University. His research focuses on drug delivery systems, nanomedicine, and combating antimicrobial resistance through innovative polymer-based approaches. He holds a Doctorate in Pharmacy and has contributed to over 50 peer-reviewed publications and patents. Education: Doctorate in Pharmacy (Pharm.D./Ph.D.) from an unspecified institution Research Interests: Dr. Bansal specializes in developing advanced drug delivery systems using renewable polymers, nanoemulsions, and lipid-polymer hybrids. His work addresses challenges in bioavailability enhancement, targeted drug delivery for multidrug-resistant pathogens, and sustainable materials in biomedicine. Recent projects include formulations for antifungal and anticancer therapies, leveraging cutting-edge techniques like ROS-regulated drug release. Projects: MADNESS: Centre of Excellence in Materials-driven Solutions for Combating Antimicrobial Resistance (Coordinator, 2024–2028) Nordic Pharmaceutical Translation and Innovation (Co-Investigator, 2024–2028) Jasmine PRO: A Versatile Platform for Drug Delivery (Co-Investigator, 2021–2024) Key Research Themes: His 15 most recent articles emphasize nanotechnology-driven solutions for drug delivery, including poly(δ-decalactone) based systems, cubosomes, and cyclodextrin complexes. These studies address topical antifungal treatments, cancer therapy, and overcoming antibiotic resistance. Labs/Teams: Active in Åbo Akademi's pharmacy research groups focusing on translational nanomedicine and sustainable biomaterials. Collaborates internationally on antimicrobial resistance initiatives.
Prof. Martin Kuentz is a Professor of Pharmaceutical Technology at the University of Applied Sciences and Arts Northwestern Switzerland (FHNW), leading the research group on Quality by Design of oral dosage forms. His primary affiliation is with the School of Life Sciences and the Institute for Pharma Technology and Biotechnology . He holds a Ph.D. in Pharmaceutical Technology from the University of Basel (1999) and a Pharmacist degree (1995). Prior to academia, he worked at F. Hoffmann-La Roche Ltd. as a Senior Scientist and Coordinator of Galenical Development Projects. Research Focus: His work centers on lipid-based formulations, amorphous solid dispersions, and computational tools for drug delivery. Key techniques include Raman spectroscopy, UV imaging, and molecular dynamics simulations. He has pioneered methods to enhance solubility of poorly water-soluble drugs using mesoporous silica, hydrophobic deep eutectic solvents (HDES), and machine learning-driven approaches. Publications & Awards: Prof. Kuentz has authored over 90 peer-reviewed articles and received awards such as the IPEC Foundation Best Manuscript Award (2014) and multiple Best Poster Awards at Swiss Pharma Science Days (2012–2015). He is a member of the American Association of Pharmaceutical Scientists (AAPS), Arbeitsgemeinschaft der Pharmazeutischen Verfahrenstechnik (APV), and the Swiss Society of Industrial Pharmacists (GSIA). Teaching: He teaches courses on industrial processes in life sciences, pharmaceutical chemistry, and quality management at both bachelor and master levels. He is certified in university didactics from the University of Basel (2008). Lab/Team: Leads the Oral Formulations for Chemical Drugs research team at FHNW. Grants/Advising: Supervises multiple Early Stage Researchers (ESRs) in the PEARRL network, including main supervision of ESR 2 and ESR 5, and co-supervision of ESR 1, 3, 4, and 6.
Professor Gabriel Harris is a faculty member in the Department of Food Science at North Carolina State University, serving as Co-Director of Undergraduate Programs. His teaching portfolio includes courses like Food Science and the Consumer, Analytical Techniques in Food and Bioprocessing Sciences, and Nutraceuticals and Functional Foods. His research focuses on understanding how food processing impacts health properties, particularly the anti-inflammatory effects of plant-based foods such as tea, chocolate, and muscadine grapes, alongside their roles in blood sugar regulation and satiety. Education includes a Ph.D. in Food Science and Nutrition from The Ohio State University (2001), M.S. in Food Science from NC State (1997), and B.S. in Home Economics from Morgan State University (1995). Research emphasizes functional foods, bioactive components, and innovative processing techniques like microwave-assisted extraction. His publications explore topics ranging from coffee's effects on athletic performance to the development of shelf-stable protein bars. Collaborations include the Foods for Health and Well-Being group. No specific awards are listed, but his work contributes to advancing food science education and nutritional health applications.
Dr Lee Yee Ying is a Senior Lecturer at the Malaysia School of Science, Monash University. She holds a PhD in Food Science and Technology from Universiti Putra Malaysia (2016), where her doctoral research focused on functional oil development via enzymatic interesterification of palm oils for obesity management. Her research interests include enzymatic/chemical modification of edible fats, functional lipid synthesis, in vivo health studies, and sustainable palm oil utilization. She teaches courses in Food Science and Functional Foods. Dr Lee has led multiple research projects, including biorefinery of microalgae and synthesis of medium-long chain triacylglycerols (MLCT). She has published over 80 peer-reviewed articles and book chapters, with a focus on lipid chemistry, structured lipids, and food product development. Notable awards include the Best PhD Award (2016) and innovation awards for plant-based milk products (2024). Her work aligns with UN SDGs related to sustainable consumption and health. Recent research trends emphasize functional lipid applications in health management, emulsion stabilization using nanocellulose, and mitigation of harmful oil processing byproducts like 3-MCPDE and glycidol esters.
Dr. Reihaneh Safavisohi is an Assistant Professor in the Department of Chemistry and Biochemistry at Seton Hall University, leading the SAFAVI Lab. Her research focuses on extracellular vesicles (EVs) for cancer biomarker detection, integrating analytical chemistry, nanotechnology, and biochemistry. Prior to this, she held postdoctoral positions at the University of Notre Dame and Michigan State University. Affiliations: Seton Hall University (2023–Present), SAFAVI Lab Director Education: Postdoctoral training at Harper Cancer Research Institute (Notre Dame), Michigan State University Research interests include EV-based diagnostics, nanoparticle protein corona dynamics, proteomic analysis via mass spectrometry, and statistical modeling for biomarker discovery. Recent work addresses sex-based differences in nanoparticle interactions and lipid nanomedicine for vaccines. She teaches graduate and undergraduate biochemistry courses and advises students in bioanalytical techniques. Grants: Recipient of Undergraduate STEM Research Grants (2024–2025) and University Research Council funding (2024). Service roles include the Seton Hall Faculty Search Committee and the Middle Atlantic Regional Meeting of the ACS.
T M Indra Mahlia , a Distinguished Professor at the School of Civil and Environmental Engineering , University of Technology Sydney (UTS), leads cutting-edge research in sustainable energy systems and environmental engineering. As a core member of the Centre for Technology in Water and Wastewater and the Centre for Advanced Modelling and Geospatial Information Systems , he bridges engineering innovation with practical climate solutions. PhD from University of Malaya (Kuala Lumpur, Malaysia) Fluency in English, Indonesian, Malay, and Achinese for peer review His research spans Techno-Economic Analysis , Circular Economy , and Water-Energy Nexus challenges, supported by over $5 million in grants. His work focuses on: Hydrogen energy systems optimization Advanced materials for energy storage Low-cost water purification technologies Sustainable biodiesel production Thermal management innovations As a Highly Cited Researcher (Clarivate Analytics, 2017-2022) and The Australian 's 2019/2025 Sustainable Energy Leader , he mentors future researchers - notably guiding two Highly Cited PhD students ( H.C. Ong and A.S. Silitonga ). His publications across 2024-2026 demonstrate technical advancements in: Hydrogen carrier systems Microalgae-derived lubricants High-entropy alloy corrosion resistance Artificial neural network optimization Phase change material thermal sinks Biohydrogen production pathways
Mansoor Amiji is a University Distinguished Professor of Pharmaceutical Sciences and Chemical Engineering at Northeastern University, with an affiliation in Bioengineering. He leads the Translational Therapeutic Delivery Laboratory, focusing on developing advanced drug delivery systems, polymeric biomaterials, and nanomedical technologies to address unmet medical needs such as cancer therapy, neurodegenerative diseases, and inflammatory conditions. His work integrates multidisciplinary expertise from engineering, biology, and medicine. Education: BS (Pharmacy, Northeastern University), PhD (Pharmaceutics, Purdue University). Awards include the T. Nagai Award and Fellowships from AAAS, AAPS, AIMBE, and the Controlled Release Society. He is a Charivate Analytics Highly Cited Author (top 1%) and recipient of the Distinguished Alumni Award from Purdue University. Research emphasizes targeted delivery systems for hard-to-deliver molecules (e.g., nucleic acids, proteins) to hard-to-reach sites like the brain. Key innovations include the Minimally Invasive Nasal Depot (MIND) technique for CNS delivery, lipid nanoparticle formulations for cancer treatment, and nanoemulsion-based combination therapies. His lab collaborates with industry and clinical partners to translate these technologies into clinical applications. Scientific achievements span over 200 publications in drug delivery, nanomedicine, and immunotherapy. His work addresses challenges in mRNA vaccine stability, overcoming chemotherapy resistance, and improving delivery of therapeutics for chronic rhinosinusitis and neurodegenerative diseases.
Dr. Michael Nickerson is a Professor and Ministry of Agriculture Strategic Research Program (SRP) Chair in Protein Quality and Utilization at the University of Saskatchewan's College of Agriculture and Bioresources, Department of Food and Bioproduct Sciences. His research focuses on optimizing plant protein utilization in food systems, with expertise in protein fractionation, functionality, and ingredient modification using pulses, oilseeds, and grains. Education: B.Sc. (Hon.) Marine Biology, Dalhousie University (1994–1998) M.Sc. Food Chemistry, Dalhousie University (1998–2001) Ph.D. Food Chemistry, Dalhousie University (2001–2004) Post-Doctorate Fellow in Food Chemistry, Dalhousie University (2004–2006) His research interests include enhancing protein quality through processes like fermentation, enzymatic hydrolysis, and thermal treatments, with applications in plant-based food innovations. He has contributed to over 50 peer-reviewed articles and holds prestigious awards such as the W.J. Eva Award (2018) and Dean’s Award for Research Excellence (2018). Current funding partners include NSERC, Saskatchewan Agriculture Development Fund, and industry collaborators. Dr. Nickerson teaches courses in food science, protein technology, and food product development at both undergraduate and graduate levels. Key Research Themes: Protein functionality and modification Plant-based ingredient optimization Pulse and oilseed valorization Food innovation for sustainability His work bridges fundamental science and industry applications, addressing challenges in sustainable food systems and protein utilization.
Ricardo Augusto Massarico Serafim is a Professor in the Department of Pharmaceutical Chemistry at IQS, University School of Engineering and Chemistry, Ramon Llull University in Barcelona, Spain. He serves as Principal Investigator for the Pharmaceutical Chemistry Research Group (Grup de Química Farmacèutica), leading a research project funded by Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) from January 2022 to June 2025. With an h-index of 10 and 564 citations across 26 research outputs, his work bridges medicinal chemistry and pharmaceutical sciences. Dr. Massarico Serafim's research focuses on developing novel therapeutic agents with particular emphasis on covalent inhibitors targeting USP7 and protein kinases, natural product-based dermatological applications, and treatments for Chagas disease. His fingerprint analysis reveals significant contributions to Protein Kinase research (91%), Cruzipain studies (66%), and investigations into natural compounds like Naringenin, Chlorogenic Acid, and their effects on Trypanosoma Cruzi. His work spans both fundamental biochemical mechanisms and applied pharmaceutical development. His recent publications demonstrate a strong trend toward covalent drug design, particularly for cancer targets like USP7 and protein kinases, while maintaining parallel research on natural flavonoids for topical applications. The 2024-2025 publications show increasing sophistication in molecular design, with multiple papers focusing on unconventional binding modes and scalable synthesis methods for covalent inhibitors. His research combines computational modeling, synthetic chemistry, and biological evaluation to develop targeted therapeutics. Among his notable scientific contributions are the development of covalent USP7 inhibitors with unconventional binding modes, scalable synthetic routes for specialized chemical probes, and comprehensive safety evaluations of natural polyphenols for topical use. His work on chlorogenic acid, apigenin, kaempferol, and naringenin has been particularly influential, with one 2024 paper accumulating 8 Scopus citations and significant social media attention. As Principal Investigator of the Pharmaceutical Chemistry Research Group, Dr. Massarico Serafim leads a multidisciplinary team of approximately 20 researchers including Borrell, Lloveras, Semino, and others. His research has received consistent funding support, with publication output showing steady growth from 1 paper in 2010 to 4 papers in 2025. His collaborations span multiple institutions, with recent external collaborations visible across various country territories as indicated in his research network map.
Karola Vorauer-Uhl is an Associate Professor at the Institute of Biochemical Engineering, Department of Biotechnology and Food Sciences, University of Natural Resources and Life Sciences, Vienna (BOKU). She is based at Muthgasse 18, Vienna, and holds a doctorate in life sciences and biotechnology. Her work is deeply rooted in biopharmaceutical technology, particularly in liposomal drug delivery and recombinant protein production. Her research interests center on advanced bioprocess technologies. She specializes in liposomal formulations for therapeutic and vaccine delivery, with a focus on protein encapsulation and liposome-protein interactions. A key methodological expertise is bio-layer interferometry (BLI) , which she uses for real-time, label-free analysis of molecular binding. Her work also encompasses CHO cell culture processes , quality by design (QbD) , process analytical technology (PAT) , and the development of recombinant proteins like erythropoietin and HIV envelope proteins for biomedical applications. The 15 most recent publications highlight a consistent research trajectory in biopharmaceutical process development and nanoparticle-based delivery systems . Early works focused on protein purification and liposome production, while recent contributions emphasize advanced analytical methods like BLI for characterizing protein-liposome interactions and implementing QbD/PAT in mammalian cell cultures. The dominant themes are liposome technology , protein characterization , and bioprocess optimization , with applications in drug and vaccine delivery. ao.Univ.Prof. (Associate Professor), BOKU Vienna Habilitation in Biopharmaceutical Technology, 2002 Promotion (PhD) in Food and Biotechnology, 1993 Dipl.-Ing. in Food and Biotechnology, 1988 Karola Vorauer-Uhl has made significant contributions to the development of liposomal therapeutics and vaccines. Her work on GMP-compliant liposome production and novel techniques like the cross-flow injection method demonstrates a strong focus on translating research into industrial applications. She has been involved in projects related to HIV vaccine development using virosomes and the therapeutic use of liposomal superoxide dismutase. Her community service includes participation in numerous scientific conferences and workshops, particularly in the fields of bioprocessing and liposome research. She is actively engaged in academic advising, as evidenced by her supervision of university theses. Her laboratory or research group appears to focus on bioprocess engineering, with expertise in recombinant protein expression, liposome formulation, and advanced analytical characterization. Collaborations with industry partners and other research institutions, especially in the area of biopharmaceuticals, are a consistent feature of her work.
Haider Sami is a researcher at the University of Vienna , affiliated with the Faculty of Life Sciences and the Department of Pharmaceutical Sciences . He works in the Macromolecular Cancer Therapeutics (MMCT) laboratory under Professor Manfred Ogris, focusing on RNA-based therapeutics and nanocarrier delivery systems . His research addresses critical challenges in splice-switching oligonucleotide (SSO) delivery , particularly regarding endosomal escape , nuclear targeting , and systemic biodistribution . Haider Sami's research expertise spans nanocarrier design for RNA splicing modulation , with a particular emphasis on redox-responsive polymers like disulfide cross-linked polyethylenimine (cLPEI) . He has pioneered methods for accelerated endosomal release and hepatic splice correction , validated through transgenic mouse models expressing split-luciferase reporters . His work demonstrates that cLPEI-SSO polyplexes significantly improve in vivo bioavailability while reducing renal excretion and enhancing tumor accumulation . Key research contributions include disulfide crosslinking strategies for endosomal escape enhancement , one-step nanoparticle synthesis using Brij-linkers , and spatiotemporal delivery tracking via NIR fluorescence imaging and X-ray computed tomography . These studies have direct implications for monogenic disease therapies and cancer treatment applications. Haider Sami has authored 24 publications since 2014, with recent work (2023-2025) emphasizing biocompatible delivery systems , quantitative biodistribution analysis , and functional protein restoration in multiple organ systems including liver, lung, kidney, and bladder.
